Sponsor:
AbbVie
Code:
NCT05407636
Conditions
AMD
nAMD
Wet Age-related Macular Degeneration
wAMD
WetAMD
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
ABBV-RGX-314 Dose 1
ABBV-RGX-314 Dose 2
Aflibercept (EYLEA®)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by AbbVie on 2025-09-25.